CASE 4-18634

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE U.S. PATENT NO. 5,677,331

ISSUED: October 14, 1997

INVENTORS: Yiqing Zhou, Dianxi Ning, Shufen Wang, Deben Ding, Guofu Li,

Chengqi Shan, and Guangyu Liu

FOR: ANTIMMALARIAL COMPOSITIONS

Mail Stop: Hatch-Waxman PTE Director for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL PATENT TERM EXTENSION APPLICATION UNDER 35 U.S.C.§156

Sir:

Applicant previously submitted an application under 35 USC §156 requesting extension of the term of the above-identified U.S. Patent No. 5,677,331. The request for extension was certified on June 5, 2009.

As discussed with Ms. Mary C. Till at the USPTO, submitted herewith are:

- (1) Statement Under 37 CFR 3.73(b); and
- (2) Power of Attorney of Revocation of Power of Attorney and Change of Correspondence Address;

which are signed by both co-owners of U.S. Patent 5,677,331: Novartis AG and Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences.

In addition, upon review by the Applicant and as noted by Ms. Mary C. Till during a telephone call, an inadvertent typographical error in the above-referenced application is discovered. Specifically, the structure of Artemether on page 2 is missing an oxygen atom.

Applicant hereby submits a Corrected Patent Term Extension Application Under 35 U.S.C.§156 to illustrate the correct chemical structure for Artemether. This typographical error had no material bearing on the substantive review of the patent term extension application as the correct structure of Artemether is illustrated at page 12 of the approved label previously submitted.

Applicant wishes to take this opportunity to thank Ms. Till for her careful review of the request and communication with the undersigned.

Respectfully submitted,

Novartis Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080

November 16, 2001

Attorney for Applicant Reg. No. 47,487 (862) 778-1202

Use Places and Designate Realignant extensibles, so persons are agreed for contents of financial medical species (1905), so persons are agreed for contents of financial medical species (1905), so persons are agreed for contents of financial medical medical species (1905), so persons are agreed for contents of financial medical medical species (1905), so persons are agreed for contents of financial medical medical species (1905), so persons are agreed for contents of financial medical medical species (1905).
STATEMENT UNDER 37 CFR 3.73HH
Applicant Palent Oxer: Novartie AG
Application Nouratent No.: -08/216, 440 /5:677, 331 Free resue Date: March 23, 1994/Octl4, 1997
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences/ Novarate/AG Novarate/AG Oreal Asserts of Communication uncounty governous according
rights that it is:
1. It the assignee of the entire right title, and interest in:
an designate of lass than the entire right title, and interest in (19th extent (by percentage) of its ownership interest is
3. The assigned of an undivided interest in the entirety of to complete assignment from one of the joint inventors was made!
and the property of the state o
A. An essignment from the inventories of the paramapolitection patent identifies above. The assignment was recorded in the United States Patent and Trademark Office at Reel . Frame
B. [X] A chain of the from the inventories of the petent applications param usabled above, to the current assignee as todows: 1. From: The document was recorded to the United States Patent and Independs Office of
The obsument was recorded in the United States Patent and Tradegraph of the Control of
Reef 008557 Frame 0400 crifer which a copy thereof a alloched
2. From: Cibe-Coins AC
TWO STOCKED IN MAIN LECTION OF THE PARTY MARKET BARRET BARRET TO THE TANK T
Real 011072 . From D019 or for which a copy thereof is altached.
3, Front:
The Bootiment was recorded in the United States Potent and Trademark Office at
Reci Frante or for which a copy thereof is adapted.
Additional documents of the citatrof allo are listed on a supplemental sheet(s).
As required by 37 CFR 3,73(b)(1)(i), the documentary evidence of the chart of this from the original owner to the assignee was by concurrently to being, submitted for recordation pursuant to 37 CFR 3.51.
[NGTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CPR Part, 3, to record the assignment of the records of the USPTO. See MPED and set
The unbegragned (whose title is supplied ballow the built prized to act on behalf of the designee.
Signature Obj. 15, 2009
Cao, Wuchun/Jennifer Chapman
Printed of Typed Name
Tide

broads in application controlled by the controlled by a user of the user of the controlled by the first and the controlled by the controll

if your need acc the rate in depressionly the hair case tradestrict or so one theret exceed a

Until the Proceeds Radran and of 1875 as recover we would	U.S. Patera and	PT0:39:81 (44) Approved by use and up (1:50/2011), Gene 0:511.4 Tioderian office, U.S. DESARTMENT OF COMPER	rë5		
India the Papersons Reduction Act of 1925, na persons the requi-	Application stumber	HEROLYMON CHRESS I REMINISTER O NOW CHREST CHREST WIND	N≑F N		
OR OF ALL	Filing Data	108/216,440	. 4		
REVOCATION OF POWER OF ATTORNEY	First Named Inventor	March 23, 1994			
WITH A NEW POWER OF ATTORNEY	Tille	ANJIMALARIAI COMPOSITIONS			
AND	Art Unit	1614	-		
CHANGE OF CORRESPONDENCE ADDRESS	Exeminer Name	Jordan, Kimberly 2	-		
	Alternay Dookel Number	118634-US-CNT2	ナ		
I hereby revoke all previous powers of attorney given in the above-identified application,					
A Priver of Alicany) is submitted there and a			1		
To energy appoint Practitionaries observations with the remaining Munither as the authorney to or agenites in prosecute the adjusted allower as no to the treat off business in the United Standard Trademork Office connected the result.	C-Mb	01095			
I hearby appears Franchionance) nembed below as my cur amin to unused all business in the United States Piston and Trail	(Magna) of Egenus) to prosec Small Oxide emperior man	tute the application identified above long			
Partitioners) Name	•	Alighagian Musika			
<u> </u>	•		1		
	,	144			
	A of	· · ·	1		
	T Abo & up t woods? I be as	WA ANI 177 +	1		
Please recognize or change the correspondence addre	ss for the shows Manth	fled application to	1		
OR The address associated with Customer Number. OR Find or Individual Nome Arthess	The state of the s				
125Y	- · · T 5107 ·	The grantemark of the resonant of the second			
County		ZI			
Tokephane	Emedi	The second contract of the second second second			
Take the Applicant loventor. OR Assigned of record of the entire interest. See of CFR 2.71 Statement cannot SFCFR 8.73(b) (Form PFC/ML) 96(c) coloraded	Processory of the same				
The state of the s	git or Assignee of Record		i		
			PH 7/2		
Name Gao, Wuchum/Jennifer Chapm	BII. Tules	None 862 778-1202	MOHIN		
Institute of Microbiology Military Medical Sciences	and Epidemiology Novartis AG	, Academy of			
NOTE विकास मार्थ करणा किया किया करणा करणा करणा करणा करणा करणा करणा करण	c o. prop debuti-apprecei vido i	equired suithful multiple tours it move transcribe			
*Total oftomns are submerted					
The extension of information is recised by 37 CFR 131, 1.32 and 1.33. The information is received in the information in the information in the information in the present and activities the completed apparatus from the induced fine the particle of the particle and activities in the particle of the particle and activities of the particle of the parti	The Action of the self by the	english rights gat proprietel code. Year, comments on contrast in our motern to stake a termines to ecclibrish			

if you paid anudance in company the form, coll 1400-PTC-0140 and event school 2

CASE 4-18634

FILING BY "EXPRESS MAI	L" UNDER 37 CFR 1.10
Express Mall Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE U.S. PATENT NO. 5,677,331

ISSUED: October 14, 1997

INVENTORS: Yiqing Zhou, Dianxi Ning, Shufen Wang, Deben Ding, Guofu Li, Chengqi Shan,

and Guangyu Liu

FOR: ANTIMMALARIAL COMPOSITIONS

Mail Stop: Hatch-Waxman PTE **Director for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

CORRECTED PATENT TERM EXTENSION APPLICATION UNDER 35 U.S.C.§156

Sir:

Pursuant to 35 U.S.C.§156 and 37 C.F.R.§1.710 et seq., Novartis AG ("Applicant"), a Corporation organized under the laws of Switzerland, hereby requests an extension of the patent term due to regulatory review of U.S. Patent No. 5,677,331, which was granted on October 14, 1997.

Applicant asserts that it is the co-owner of the right, title and interest in U.S. Patent No. 5,677,331 by virtue of an assignment from the inventors Yiqing Zhou, Dianxi Ning, Shufen Wang, Deben Ding, Guofu Li, Chengqi Shan, and Guangyu Liu, to Ciba-Geigy AG (which later becomes part of Novartis AG through a merger) and Institute of Microbiology, Academy of Military Medical Sciences.

The assignment and the merger are recorded in the U.S. Patent and Trademark Office at Reel 008557, Frame 0400 on June 19, 1997 and Reel 011072, Frame 0019 on October 31, 2000, respectively.

Applicant asserts that the undersigned counsel, Jennifer C. Chapman, is authorized to act as its attorney in this matter.

In accordance with 35 U.S.C.§156 and 37 C.F.R.§1.740, Applicant provides the following information in support of its request for a patent term extension.

(1) Identification of the Approved Product

The approved product is Coartem[®], which is a fixed combination of two antimalarial active ingredients: artemether and lumefantrine, having the chemical structure(s)

Artemether

and

Lumefantrine

respectively.

The chemical name of artemether is (3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine.

The chemical name of lumefantrine is (\pm) -2-dibutylamine-1-[2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluorene-4-yl]ethanol.

The strength is 20mg/120mg, artemether / lumefantrine respectively.

The approved product is a tablet for oral administration.

The approved product is indicated for the treatment of acute, uncomplicated malaria infection due to *Plasmodium falciparum* in patients of 5 kg bodyweight and above.

A copy of the approved label for Coartem® is attached hereto as Appendix A.

2. Identification of the Federal Statute under which Regulatory Review Occurred

The approved product was subject to regulatory review under the Federal Food, Drug and Cosmetic Act, Section 505(b) (21 U.S.C.§355(b)).

3. The Date of Permission for Commercial Marketing

The approved product received permission for commercial marketing under Section 505(c) of the Federal Food, Drug and Cosmetic Act (21 U.S.C.§355(c)) on April 7, 2009. A copy of the FDA approval letter is attached hereto as Appendix B.

4. Active Ingredlent Statement

There are two active ingredients in Coartem®: artemether and lumefantrine.

Neither artemether nor lumefantrine has been previously approved for commercial marketing or use under Section 505 of the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, or the Virus-Serum Toxin Act prior to the approval of NDA 22-268 by the United States Food and Drug Administration on April 7, 2009.

5. Statement of Timely Filing

The last day on which this application could be submitted is June 6, 2009 which is 60 days after the approval of NDA 22-268 on April 7, 2009. This application is timely filed on or prior to June 6, 2009.

6. Identification of Patent for which Extension is Sought

This application seeks to extend the term of U.S. Patent No. 5,677,331, which issued October 14, 1997 to Yiqing Zhou, Dianxi Ning, Shufen Wang, Deben Ding, Guofu Li, Chengqi Shan, and Guangyu Liu, the term of which would otherwise expire on October 14, 2014.

7. Patent Copy

A complete copy of U.S. Patent No. 5,677,331, identified in paragraph 6 above, is attached as Appendix C.

8. Post-Issuance Activity Statement

No disclaimer, certification of correction, reexamination certificate or reissue has been filed, issued or requested with respect to U.S. Patent No. 5,677,331.

All maintenance fees have been timely paid. The 4th year maintenance fee was paid on April 2, 2001. The 8th year maintenance fee was paid on April 1, 2005. The 12th year maintenance fee was paid on March 18, 2009. Copies of the Maintenance Fee Statements are attached hereto as Appendix D.

9. <u>Statement Showing How the Claims of the Patent for which Extension is Sought</u> <u>Cover the Approved Product</u>

The claims of U.S. Patent No. 5,677,331 cover the approved product (claims 1-4), and a method of using the approved product (claim 5).

Claim 1 of U.S. Patent No. 5,677,331 reads as follows:

1. A pharmaceutical composition to be administered orally to humans, suitable for synergistic action of the combined active components against malaria, which composition consists of a synergistic antimalarially effective amount of a combination of the compound benflumetol of the formula:

in fixed combination with the compound artemether of the formula:

wherein one of R and R_1 individually represents methoxy, and the other represents hydrogen,

and pharmaceutically acceptable additives.

The approved product is a fixed combination of artemether (as in formulation (II) of claim 1 of U.S. Patent No. 5,677,331) and lumefantrine (as in formulation (I) of claim 1 of U.S. Patent No. 5,677,331). The approved product is an oral dosage form, and it is for the treatment of malaria. Hence, claim 1 covers the approved product.

Claim 2 of U.S. Patent No. 5,677,331 reads as follows:

2. A pharmaceutical composition according to claim 1, which composition consists of a synergistically effective amount of one to ten parts by weight of benflumetol (I) for each part by weight of artemether (II).

Coartem[®] tablets contain 20mg of artemether and 120mg of lumefantrine. The weight ratio of lumefantrine/artemether is 6, between 1 to 10 as required by claim 2. Hence claim 2 covers the approved product.

Claim 3 of U.S. Patent No. 5,677,331 reads as follows:

3. A pharmaceutical composition according to claim 1, which composition consists of a synergistically effective amount of three to seven parts by weight of benflumetol (I) for each part by weight of artemether (II).

Coartem® tablets contain 20mg of artemether and 120mg of lumefantrine. The weight ratio of lumefantrine/artemether is 6, between 3 to 7 as required by claim 3. Hence claim 3 covers the approved product.

Claim 4 of U.S. Patent No. 5,677,331 reads as follows:

4. A pharmaceutical composition according to claim 1 which composition consists of a synergistically effective amount of five to six parts by weight of benflumetol (i) for each part by weight of artemether (II).

Coartem[®] tablets contain 20mg of artemether and 120mg of lumefantrine. The weight ratio of lumefantrine/artemether is 6, between or equal to 5 to 6 as required by claim 3. Hence claim 3 covers the approved product.

Claim 5 of U.S. Patent No. 5,677,331 reads as follows:

5. A method of treating malaria which comprises administering orally to a human in need of such treatment a synergistic antimalarially effective amount of a combination of benflumetol of formula (I) and artemether of formula (II).

The approved product is indicated for the treatment of acute, uncomplicated malaria infection due to *Plasmodium falciparum* in patients of 5 kg bodyweight and above. Hence, claim 5 covers the method of using the approved product.

10. Statement of the Relevant Dates to Determine the Regulatory Review Period

The relevant dates and information pursuant to 35 U.S.C.§156(g) to enable the Secretary of Health and Human Services to determine the applicable regulatory review period are as follows:

The patent for which extension of the term thereof is sought claims a human drug product. The human drug product is a composition containing artemether and lumefantrine.

- (A) No investigational new drug (IND) application was filed prior to the approval of the approved product. An IND was filed after the approval of the approved product in order to submit post-approval data. The IND number is 105,588.
- (B) A New Drug Application (NDA) for Coartem® was received by the Department of Health and Human Services on June 27, 2008 and granted NDA No. 22-268.
 - (C) NDA No. 22-268 was approved on April 7, 2009.

11. Brief Description of Activities Undertaken During the Regulatory Review Period

As a brief description of the activities undertaken during the applicable regulatory review period, attached hereto as Appendix E is a chronology of the major communications between the U.S. Food and Drug Administration and the Applicant in NDA No. 22-268.

12. Opinion of Eligibility for Extension

Applicant is of the opinion that U.S. Patent No. 5,677,331 is eligible for extension under 35 U.S.C.§156 and 37 C.F.R.§1.720 because it satisfies all of the requirements for such extension as follows:

(a) 35 U.S.C.§156(a) and 37 C.F.R.§1.720(a)

U.S. Patent No. 5,677,331 claims a human drug product, a pharmaceutical composition containing fixed combination of two active ingredients artemether and lumefantrine.

MPEP 2751 states:

"A patent is considered to claim the product at least in those situations where the patent claims the active ingredient per se, or claims a composition or formulation which contains the active ingredient(s) and reads of the composition or formulation approved for commercial marketing or use"

(b) 35 U.S.C.§156(a)(1) and 37 C.F.R.§1.720(g)

The term of U.S. Patent No. 5,677,331 (expiring October 14, 2014) has not expired before the submission of this application.

(c) 35 U.S.C.§156(a)(2) and 37 C.F.R.§1.720(b)

The term of U.S. Patent No. 5,677,331 has never been extended.

(d) 35 U.S.C.§156(a)(3) and 37 C.F.R.§1.720(c)

The application for extension of the term of U.S. Patent No. 5,677,331 is submitted by the authorized attorney of the co-owner of record thereof in accordance with the requirements of 35 U.S.C.§156(d) and 37 C.F.R.§1.740.

(e) 35 U.S.C.§156(a)(4) and 37 C.F.R.§1.720(d)

The approved product, Coartem®, has been subjected to a regulatory review period before its commercial marketing or use.

(f) 35 U.S.C.§156(a)(5)(A) and 37 C.F.R.§1.720(h)

No other patent has been extended for the same regulatory review period for the approved product, Coartem®.

13. Length of extension claimed under 37 C.F.R.§1.740(a)(12)

The length of extension of the patent term of U.S. Patent No. 5,677,331 requested by Applicant is <u>284 days</u> (till <u>July 25, 2015</u>) which length was calculated in accordance with 37 C.F.R.§1.775 as follows:

- (a) The regulatory review period under 35 U.S.C.§156(g)(1)(B) began on June 27, 2008 (the effective date of the NDA) and ended on April 7, 2009 (the approval date), amounting to a total of 284 days which is the period of (i) and (ii) below:
 - (i) The period of review under35 U.S.C. $\S156(g)(1)(B)(i)$, the "Testing Period," which is 0 days;
 - (ii) The period of review under 35 U.S.C.§156(g)(1)(B)(ii), the "Application Period," began on June 27, 2008 and ended on April 7, 2009, which is 284 days;
- (b) The regulatory review period upon which the period for extension is calculated is the entire regulatory review period as determined in subparagraph (13)(a) above (284 days) less:
 - (i) The number of days in the regulatory review period which were on or before the date on which the patent issued (October 14, 1997), i.e., 0 days, and
 - (ii) The number of days during which the Applicant did not act with due diligence, i.e., 0 days, and
 - (iii) One-half of the number of days remaining in the period in subparagraph (13)(a)(i) after subtracting the number of days in subparagraphs (13)(b)(i) and (13)(b)(ii), which is one-half of (0 [0 + 0]) or 0 days;

which results in a period of 284-0=284 days.

(c) The number of days as determined in subparagraph (13)(b), when added to the original term (October 14, 2014), would result in the date of July 25, 2015.

P. 16

- (d) Fourteen (14) years when added to the date of the NDA Approval Letter (April 7, 2009) would result in the date of April 7, 2023.
- (e) The earlier date as determined by subparagraphs (13)(c) and (13)(d) is July 25, 2015.
- (f) Since the original patent was issued after September 24, 1984, the extension otherwise obtainable is limited to not more than five (5) years. Five years, when added to the original expiration of U.S. Patent No. 5,677,331 (October 14, 2014), results in the date October 14, 2019.
- (g) The earlier date as determined in subparagraphs (13)(e) and (13)(f) is July 25, 2015.

Duty of Disclosure Acknowledgement Under 37 C.F.R.§1.740(a)(13) 14.

Applicant acknowledges a duty to disclose to the Director of the United States Patent and Trademark Office and the Secretary of Health and Human Services any information which is material to the determination of entitlement to the extension sought.

15. Fee Charge

The prescribed fee for receiving and acting upon this application is to be charged to Applicant's Deposit Account No. 19-0134 as authorized in the attached transmittal letter, submitted in triplicate.

Correspondence Address Required by 37 C.F.R.§1.740(a)(15) 16.

All correspondence relating to this application for patent term extension should be addressed to:

> Jennifer C. Chapman Novartis One Health Plaza, Bldg. 101 East Hanover, NJ 07936-1080

Certification Under 37 C.F.R.§1.740(b) 17.

The undersigned hereby certifies that the instant application, including its attachments and supporting papers, is being submitted as one original and two copies thereof in accordance with 37 C.F.R.§1.740(b).

Respectfully submitted,

Novartis Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080

November 16 200f

Attorney for Applicant Reg. No. 47,487

(862) 778-1202

The state of states of states of the states of property of the states of
STATEMENT UNDER 37 CFR 3.73(H)
Applicantipation Owner: Novartin AC
Application No. Restant No.: - G8/216,440 /5:677,331 Filed Save Date: March 23, 1994/Oct14, 199.
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences/ Novartim/AG .e University/Gotporation from a sergent of communication of communication of sergent of communication of sergent o
1. It it assigned of the entire right, title, and interest in:
an designer of lass than the entire right title, and interest in (The extent (by percentage) of its ownership interest is (***), or
3. The assignee of an undivided interest in the entirety of a complete assignment from one of the John Inventors was made!
An assignment from the inventories of the paramapphication palant identities above. The assignment was recorded in the United States Patent and Trademark Office at Real
B. A chain of the from the inventorial of the perchi application potent identified above, to the current assignee as information. 1. From: To: The document was recorded in the United States Patent and Tradegray Office at Reel 008557 Frame 0400 Critician Compy thereof is alterned.
2, From: 6-1 - 10 mich a copy thereo're allowed
To: Novartie AC. The decument was recorded to the United States Paters and Trademark Office at States Paters and To:
The document was recorded in the United States Potent and Trademurk Office at
Prame as for which a copy thereof is adjacent
Additional decembers of the chart of the are inted on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(t), the documentary evidence of the chair of this from the original owner to the designed was. by concurrently is being, submitted for recordation pursuant to 37 CFR 3.51. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be appropriate to Assignment officials in accordance with 37 CFR Part, 3, to record the assignment in the records of the USPTO. See MPEP 302 66]
the unideragned (whose title is supplied before outborized to act on behalf of the assignee.
Signature (bt. 15, 200)
Cao, Wuchun/Jennifer Chapman
Printed or Typed Warne Diffector/Petent Attorney
Title Ti

The collection of inflating one particles of set as 254%. The instruction is required to obtain of relating that for the policy currents in the united the property of the collection of the col

il you then are the use in remaining the first care i-dustries of 90 use their excess c

Under the Papersons Reduction Act of 1956, no persons are requi	U,S. Patera and 1 90 to respond to a control of in	Howard by use hower 11-50/2011, GMB 6551400 Doctrials office, U.S. DEPARTMENT OF COMPURED Manager of the Computer of the Computer of Compu			
POWER OF ATTORNEY	Application Muniber		er L		
O'R	Filing Data	108/216,440	7		
REVOCATION OF POWER OF ATTORNEY	First Named Inventor	March 23, 1994	.4		
WITH A NEW POWER OF ATTORNEY	Title	Viging Zhou	4		
AND	Art Unit	ANTIMALARIAI. COMPOSITIONS	4		
CHANGE OF CORRESPONDENCE ADDRESS	Examiner Name		1		
CHARLES CORRESPONDENCE ADDRESS	Attorney Dookel Number	Jordan, Kimberly R.	}		
I hereby revoke all previous powers of attorney given in the above-identified application.					
A Priver of Anamyy is submitted hereanth					
OR Thereby appoint Providence of the estimate with the estimated Monthly of the continued of the state of t	Collection Collection	01095			
I hearby appearal Practitions and named below as my our atom to unusual all thousans in the United States Petrol and Trails	nage of expense of Maker Sent became soon	ite the application identified above, and with			
Practitioners; Name	*	agnorium Nurstan			
	•	· · · · · · · · · · · · · · · · · · ·			
1					
	* v1 .	47 1 7	•		
Please recognize or change the correspondence address The address assectated with the draws mentioned Customer to or The address associated with Customer Mander.	Number				
OR Fine or Individual Name Address	The second of th				
County		2/3			
Tologopa =					
' and the	Edwil				
Applicant Inventor					
Assigned of recircled the entire interest. See 37 CFR 9,71 statement cones. SF CFR 8 73(b) (Form PFC/SALVS) enamined to	merend a sied on				
SIGNATURS OF Applican		Andrewson of the state of the s			
Sylphicistres Clarest of Organist	CI CORDA TIME	TOGETE	1+2/204		
Name Gao, Wuchun/Jennifer Chapma	Telépi	862 778-1202	portra		
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences/Novartis AG					
No.15: Advance ask promote a strikes of letted of the superindent.	OTE Eligibulish of will the limethous or ascigness of fecord of the state indirector than departmental being the indirect such the multiple forms it more from the				
*Total ofterms are submeded					
Ine expection of information is remard by 37 OFR 1-31, 1-32 and 1-33. The information to provide an opplication, somble and by a source, 2 33 -0 5 < 123, and information to provide an opplication of the confidence of the control of the confidence	a John . They was vary and	and the moters to take a countries to complete.			

if you pand anudance in company the form, coll 1-800-PTD-0190 and search school 2

() NOVARTIS

One Health Plaza Bldg. 101, 2nd Floor East Hanover, NJ 07936

Patents Pharma

Fax Cover Sheet

Date: 1//6/19 Time: _	AM PM
• •	(circle one)
Number of Pages (including cover sheet): 17	
To: MARY TILL	_ Phone: ()
Location: USPTO	Fax: (571) <u>A173 - 7155</u>
cc:	
From: Jennifer Chapman	Phone: (862) 778-1262
	Fax: (973) <u>781-8064</u>
RE: COARden, US PATENT N	5,617,331 PTE
MESSAGE;	
·	
CERTIFICATE OF FACSIMILE TRANS	MISSION

CONFIDENTIALITY NOTICE

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the

Palent and Trademark Office on the date shown below.

Type or print name

THIS FAX CONTAINS CONFIDENTIAL INFORMATION WHICH MAY BE PRIVLEGED AND IS INTENDED SOLELY FOR THE USE OF THE ABOVE-NAMED RECIPIENTIS), IT MAY BE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT AN INTENDED RECIPIENTIS) OR PERSON RESPONSIBLE FOR DELIVERY OF THIS FAX TO AN INTENDED RECIPIENTIS), YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECIPIED THIS FAX IN ERROR AND THAT ANY REVIEW, DISSEMINATION DISCLOSURE, COPYING OR OTHER USE OF THIS FAX OR ITS CONTENTS IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FAX IN ERROR. PLEASE NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE AT ONE OF THE PHONE NUMBERS SET FORTH ABOVE AND DESTROY THE FAX IN ERROR.

PAGE 1/17 * RCVD AT 11/16/2009 1:34:55 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/25 * DNIS:2737755 * CSID: * DURATION (mm-ss):02-06